Dermorphin vs Cerebrolysin
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
DermorphinCognitive EnhancementAnti-Aging & Longevity
Cerebrolysin- Summary
- Dermorphin is a naturally occurring heptapeptide opioid isolated from the skin of South American phyllomedusine frogs. It is one of the most potent endogenous mu-opioid receptor agonists known, approximately 30-40 times more potent than morphine by weight. Explored for pain management and fatigue modulation.
- Cerebrolysin is a porcine brain-derived neuropeptide complex that mimics the action of endogenous neurotrophic factors (BDNF, NGF, GDNF, NT-3). It promotes neurogenesis, neuroprotection, and synaptic plasticity, and is approved in many countries for stroke, traumatic brain injury, and Alzheimer's disease.
- Half-Life
- Estimated 30-60 minutes (longer than endorphins due to D-Ala)
- Variable for the complex; individual peptide fractions: minutes to hours
- Admin Route
- Subcutaneous (research), Intrathecal (research), Intranasal (research)
- IV, IM
- Research
- —
- —
- Typical Dose
- Not established for human use; research doses vary widely
- 5–10 mL
- Frequency
- Not established
- Daily for 10–20 days
- Key Benefits
- Potent analgesia superior to morphine on a per-weight basis
- May reduce perception of fatigue in high-intensity activity
- Longer-lasting than endogenous opioids due to D-amino acid substitution
- Research tool for mu-opioid receptor pharmacology
- Potential therapeutic application in refractory pain
- Promotes neurogenesis and synaptic plasticity
- Approved for stroke rehabilitation (accelerates recovery)
- Alzheimer's disease: slows progression and improves cognition
- Traumatic brain injury recovery
- Enhances memory and executive function
- Neuroprotection against oxidative stress and excitotoxicity
- Anti-amyloid and anti-tau effects
- Mood improvement and reduced anxiety
- Side Effects
- High addiction and dependence potential (mu-opioid agonism)
- Respiratory depression at high doses
- Nausea, vomiting, constipation
- Sedation and cognitive impairment
- +2 more
- Generally well tolerated
- Mild nausea and dizziness (IV infusion)
- Headache at initiation
- Rare: agitation (usually at very high doses)
- +2 more
- Stacks With
- —
- —